INCYTE CORP - 8-K Filing
Incyte Corporation reached a settlement with the Centers for Medicare & Medicaid Services (CMS) regarding the application of Medicaid rebate rules to Opzelura®. The agreement resolves litigation by ensuring CMS will not treat Opzelura as a line extension of Jakafi®, leading Incyte to withdraw its lawsuit. The company expects a one-time, non-cash benefit of approximately $246 million in Q2 2026 and anticipates improved gross-to-net for Opzelura moving forward. (Items: 8.01 Other Events)
Tickers: $INCY